Novel immunotherapy regimens, PD-1/PD-L1, and CTLA-4 checkpoint inhibitors, and CAR T cells have shown promising potential in the treatment of patients with DLBCL. This evidence concerns the gene CTLA4 and diffuse large B-cell lymphoma.